Pre-emptive Abdominal Aortic Aneurysm Sac Embolization During EVAR
Launched by RIGSHOSPITALET, DENMARK · Oct 8, 2022
Trial Information
Current as of August 19, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new approach to treat abdominal aortic aneurysms (AAAs), which are bulges in the main blood vessel that can be dangerous if they rupture. The researchers want to see if a procedure called "sac embolization," done before a standard treatment called endovascular abdominal aortic repair (EVAR), can improve outcomes for patients. This trial is specifically looking at patients with AAAs that are large enough to need treatment but have not yet ruptured.
To be eligible for this trial, participants need to be adults aged 18 and older with a specific size of AAA—55mm for men and 50mm for women. Those who have a ruptured AAA or cannot participate for other reasons will not be included. If someone joins the trial, they can expect to undergo the new procedure along with the standard treatment and will be closely monitored for their recovery. This research aims to find out if this new approach can make a difference in how well patients do after their treatment.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient with 55mm (male) or 50 mm (female) AAA, available for EVAR
- • \> 18 year old
- Exclusion Criteria:
- • Not accept to participate
- • Ruptured AAA
- • Outside for instruction for the use EVAR
About Rigshospitalet, Denmark
Rigshospitalet, located in Copenhagen, Denmark, is one of the leading hospitals in Scandinavia and a prominent center for clinical research and innovation. As a key academic institution affiliated with the University of Copenhagen, Rigshospitalet is dedicated to advancing healthcare through rigorous clinical trials and groundbreaking research across various medical disciplines. The hospital’s commitment to excellence is reflected in its multidisciplinary approach, collaboration with international research networks, and focus on improving patient outcomes through evidence-based practices. With state-of-the-art facilities and a team of highly qualified professionals, Rigshospitalet plays a crucial role in translating scientific discoveries into effective treatments and therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials